Related Experiment Video
Updated: Nov 21, 2025

Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 1. Biosafety Level 4 Suit Laboratory Suite Entry and Exit Procedures
Published on: October 3, 2016
Risk-Based Selection of Environmental Classifications for Biopharmaceutical Operations
Nick Bevan1, Tim Corbidge2, David Estape3
1Alexion Pharma International Operations UC, Blanchardstown, Dublin, Ireland.
This study introduces a risk-based method for assigning environmental classifications in biopharmaceutical manufacturing. It shows that closed systems reduce the need for cleanrooms, lowering costs without impacting product quality or patient safety.
Area of Science:
- Pharmaceutical Manufacturing
- Environmental Risk Assessment
- Biopharmaceutical Facilities
Background:
- Current biopharmaceutical facility designs often exceed necessary environmental controls for non-sterile drug substance manufacturing.
- Technological advancements, particularly closed systems, allow processes to occur in controlled environments, yet facility designs lag behind.
- Overly complex facility designs lead to increased capital and operational costs.
Purpose of the Study:
- To propose a formal risk assessment-based methodology for assigning environmental classifications during the early design phase of biopharmaceutical facilities.
- To facilitate the selection of appropriate environmental conditions for different process steps.
- To support the implementation of closed systems and reduce the reliance on classified cleanrooms.
Main Methods:
- Developed a risk assessment methodology evaluating environmental contamination risk to product quality and patient safety.
- Assessed factors including growth potential (time, nutrients, temperature), bioburden limits, system closure level, and contamination detectability.
- Defined practical criteria for closed systems, building on International Society for Pharmaceutical Engineering (ISPE) guidance.
Main Results:
- The methodology assigns environmental classifications based on a formal risk assessment.
- Closed system operations are determined to require only controlled, not classified, environments.
- The study demonstrated that increased environmental classification beyond controlled levels offers no additional product protection for closed systems.
Conclusions:
- The proposed risk-based methodology effectively reduces facility complexity and costs.
- Implementing closed systems significantly minimizes the need for classified areas in biopharmaceutical manufacturing.
- This approach ensures patient safety and product quality while optimizing facility design and operational expenses.
More Related Videos
09:30Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
05:34Operating and Biocontainment Procedures of a Facility for Laboratory Mice with a Natural Microbiome: Immunophenotyping Procedure
Published on: December 13, 2024
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Products: Biologics, Biosimilars and Interchangeables
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Classes and Categories
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence